References

  1. Laurin D, Hannani D, Pernollet M, Moine A, Plumas J, Bensa, J-C, Cahn J-Y, Garban F (2009) Immunomonitoring of graft-versus-host minor histocompatibility antigen correlates with graft-versus-host disease and absence of relapse after graft Transfusion Oct 15. [Epub ahead of print]

  2. Bartholdy C, Christensen JE, Grujic M, Christensen JP, Thomsen AR (2009) T-cell intrinsic expression of MyD88 is required for sustained expansion of the virus-specific CD8+ T-cell population in LCMV-infected mice J Gen Vir 90, 423-431

  3. Andersen MH, Sørensen RB, Brimnes MK, Svane IM, Becker JC, thor Straten P (2009) Identification of heme oxygenase-1-specific regulartory CD8+ T cells in cancer patients J Clin Invest 119(8)2245-2256

  4. Sørensen RB, Junker N, Kirkin A, Voigt H, Svane IM, Becker JC, thor Straten P, Andersen MH (2009) The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines Cancer Immunol Immunother 58:665–675

  5. Bonefeld CM, Haks M, Nielsen B, von Essen M, Boding L, Hansen AK, Larsen JM, Ødum N, Krimpenfort P, Kruisbeck, A, Christensen JP, Thomsen AR, Geisler A. (2008) TCR Down-regulation controls virus-specific CD8+ T cell responses J.Immunol Dec1;181(11):7786-99

  6. de Goër de Herve, M-G, Cariou A, Simonetta F, Taoufik Y (2008) Heterospecific CD4 Help to Rescue CD8 T Cell Killers J.Immunol Nov1;181(9)5974-80

  7. Berntsen A, Trepiakas R, Wenandy L, Geertsen PF, thor Straten P, Andersen MH, Pedersen AE, Claesson M, Lorenzen T, Johansen, Svane IM (2008) Therapeutic Dendritic Cell Vaccination of Patients With Metastatic Renal Cell Carcinoma: A Clinical Phase 1/2 trial J Immunotherapy 31(8)771-780

  8. Kollgaard T, Hadrup SR, Petersen SL, Masmas TN, Andersen MH, Spierings E, Vindeløv L, thor Straten P (2008) Natural T-cell responses against minor histocompatibilty antigen (mHag) HY following HLA-matched hemapoietic celll transplantation: what are the requirements for a “good” mHag? Leukemia 22(10)1948-51

  9. Abraham R (2008) Identification of CTL Epitopes on BK Virus VP1 Protein for Assesment of Immunologic Competance in Transplant-Associated BK Nephropathy J Allergy Clin Immunol 121(2)S170

  10. Broimans RA, Boyce CS, Popma J, Broyles DA, Gratama JW, Southwick PC, Keeney M (2008) Analytical Performance of a Standardized Single-Platform MHC Tetramer Assay for the Identification and Enumeration of CMV-Specific CD8+ T Lymphocytes Cytometry 73A:992-1000

  11. Svane IM, Pedersen AE, Nikolajsen K, Zocca M-B (2008) Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2 Vaccine 2008 July 9;26:4716-4724

  12. Machlenkin A, Uzana R, Frankenburg S, Eisenberg G, Eisenbach L, Pitcovski J, Gorodetsky R, Nissan A, Peretz T, Lotem M (2008) Capture of tumor cell membranes by trogocytosis facilitates detection and isolation of tumor-specific functional CTLs Cancer Res. 2008 Mar 15;68(6):2006-13

  13. Holst PJ, Orskov C, Qvortrup K, Christensen JP, Thomsen AR (2007) CCR5 and CXCR3 are dispensable for liver infiltration, but CCR5 protects against virus-induced T-cell-mediated Hepatic Steatosis J Virol, Sept 2007, 10101-10112

  14. Holst PJ, Bartholdy C, Stryhn A, Thomsen AR, Christensen JP (2007) Rapid and sustained CD4+ T-cell-independent immunity from adenovirus-encoded vaccine antigensJ Gen Virol Jun;88(Pt6):1706-16

  15. Bartholdy C, Kauffmann SO, Christensen JP Thomsen AR (2007) Agonistic anti CD-40 antibody profoundly suppresses the immune response to infection with lymphocytic chriomeningitis virus J Immunol 178:1662-1670

  16. Houtenbos I, Westers TM, Dijkhuis A, de Gruijl TD, Ossenkoppele GJ, van de  Loosdrecht AA (2007) Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting Clin Cancer Res Jan1;13(1)307-15

  17. Svane IM, Pedersen AE, Johnsen HE, Nielsen D, Kamby C, Nikolajsen S, Ottesen S, Zocca M, Johansen JS, Claesson MH (2006) Dendritic cells loaded with wild-type p53 peptides induce T cell immunity and disease stabilization in patients with advanced breast cancer (Abstract)J Clin Oncol 24(18Suppl)June, 2577

  18. Gupta AJ, Leung E, Mi H, Carter V, Anand V, Chatopadhyay, Shenton B, Kirby J, Talbot D (2006) Assesment of variation in Epstein-Barr virus specific T cells following transplantation using MHC class I-peptide complexes (Abstract)Transplantation Suppl. Abstract #253 (PO-151) www.wtc2006.org

  19. Hadrup SR, Braendstrup O, Jacobsen GK, Mortensen S, Pedersen LO, Seremet T, Andersen MH, Becker JC, Straten PT (2006) Tumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cells Int J Cancer 2006 Aug 15;119(4):831-8

  20. Sorensen RB, Hadrup SR, Kollgaard T, Svane IM, thor Straten P, Andersen MH (2006) Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient Cancer Immunol Immunother Apr;56(4)527-33

  21. Hadrup SR, Gehl J, Sorensen RB, Geetsen PF, thor Straten P, Andersen MH (2006) Persistence of survivin specific T cells for seven years in a malignant melanoma patient during complete remission Cancer Biol Ther May 5:5, 480-2

  22. Christensen JE, de Lemos C, Moos T, Christensen JP, Thomsen AR (2006) CXCL10 is the key ligand for CXCR3 on CD8+ effector T-cells involved in immune surveillance of the LCMV-infected CNS J Immunol Apr 176(7):4235-43

  23. Batard P, Peterson DA, Devêvre E, Guillaume P, Cerottini J-C, Rimoldi D, Speiser DE, Winther L, Romero P (2006) Dextramers: New generation of fluorescent MHC classI/peptide multimers for visualization of antigen-specific CD8 T cells J Immunol Methods March 20;310(1-2)136-48

  24. Hadrup SR, Strindhall J, Kollgaard T, Seremet T, Johansson B, Pawelec G, thor Straten P, Wikby A (2006) Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional CMV specific T cells in the very elderly J Immunol (Feb) 176(4)1645-53

  25. Storm P, Bartholdy C, Sørensen MR, Christensen JP, Thomsen AR (2006) Perforin-deficient CD8+ T cells mediate fatal lymphocytic choriomeningitis despite Impaired cytokine production J Virol Feb 80(3)1222-1230

  26. thor Straten P, Dahl C, Schrama D, Pedersen LØ, Andersen MH, Seremet T, Bröcker E-B, Guldberg P, Becker JC (2006) Identification of identical TCRs in primary melanoma lesions and tumor free correspsonding sentinel lymph nodes Cancer Immunol Immunother May;4(5)399-409

  27. Otto K, Andersen MH, Eggert A, Keikavoussi P, Pedersen LØ, Rath JC; Böck M, Bröcker E-B, thor Straten P, Kämpgen E, Becker JC (2005) Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin Vaccine Jan4;23(7)884-9

  28. Berger TG, Haendle I, Schrama D, Lüftl M, Bauer N, Pedersen LØ, Schuler-Thurner B, Hohenberger W, thor Straten P, Schuler G, Becker JC (2004) Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocytes-derived dendritic cells Int J Cancer 111,229-37

  29. Andersen MH, Reker S, Becker JC, thor Straten P (2004) The Melanoma Inhibitor of Apoptosis Protein: A Target for Spontaneous Cytotoxic T Cell Response J Invest Dermatol 122:392-399

  30. Schrama D, Eggert AAO, Bröcker E-B, Pedersen LØ, thor Straten P, Becker JC (2003) Immunological consequences of the sentinel lymph-node biopsy-lessons from a melanoma patient Lancet Oncol 4:446-47

  31. Schrama D, Pedersen LØ, Keikavoussi P, Andersen MH, thor Straten P, Bröcker E-B, Kämpgen E, Becker JC (2002) Aggregation of Antigen-Specific T Cells at the Inoculation Site of Mature Dendritic Cells J Invest Dermatol 119:1443-48

  32. Andersen MA, Petersen LØ, Capeller B, Bröcker E-B, Becker JC, thor Straten P (2001) Spontaneous cytotoxic T-cell responses against Survivin-derived MHC class I-restricted T-cell epitopes in Situ as well as ex vivo in cancer patients Cancer Res, Aug, 61,5964-68

 

Products and support
If you need information concerning Immudex products, have a technical enquiry, or are interested in customer-defined Dextramers and/or collaboration with Immudex, please contact us on Email customer@immudex.com
If you need ordering information, please contact us on Email ordering@immudex.com

Terms & ConditionsTerms & Conditions Privacy StatementPrivacy Statement Legal NoticeLegal Notice and Disclaimer

Home About Us The Dextramer™
Technology MHC Dextramer™
Performance
Staining Procedures
Tips & Tricks
Flow Cytometer
Set-Up
References
Products & Ordering Distributors in Japan Contact Information